Costco sells Celltrion's Yuflyma Low WAC in US

The S.Korean firm's autoimmune disease drug was registered in the Costco Membership Prescription Program

Costco sells Celltrion's Yuflyma Low WAC in US
Jeong Min Nam 1
2024-08-13 16:57:37 peux@hankyung.com
Bio & Pharma

South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now available for purchase at Costco in the US.

According to Celltrion, Yuflyma was registered earlier this month under the Costco Membership Prescription Program (CMPP) at a low wholesale acquisition cost (WAC).

CMPP is a program that allows Costco members to purchase medications at discounted prices at in-store pharmacies or affiliated pharmacies.

Starting this month, uninsured Costco members and their dependents can purchase Yuflyma at a discounted price in Costco stores and affiliated pharmacies across the United States at a reduced wholesale price.

The National Center for Health Statistics of the US Centers for Disease Control and Prevention (CDC) reported that the number of uninsured individuals in the US reached 27 million in the first quarter of 2024.

Write to Jeong Min Nam at peux@hankyung.com
#Celltrion #Yuflyma #adalimumab #Costco #CMPP #WAC #biosimilar

Celltrion gets FDA nod for Keytruda copy's phase 3 clinical trials

Celltrion gets FDA nod for Keytruda copy's phase 3 clinical trials

Celltrion booth at the BIO International Convention 2024 in San Diego, June 2024 (Courtesy of Yonhap) Celltrion Inc., South Korea’s biosimilar giant, will proceed with phase 3 trials for global blockbuster drug Keytruda’s copycat CT-P51, a treatment for non-small cell lung cancer, a

Celltrion's Zymfentra joins US insurance-covered drug lists

Celltrion's Zymfentra joins US insurance-covered drug lists

South Korean biosimilar maker Celltrion Inc. said on Monday that its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), has joined the insurance-covered drug lists by three major US Prescription Benefit Managers (PBMs) after its US launch in March.The three PBM

Celltrion gets approval of Steqeyma in Canada

Celltrion gets approval of Steqeyma in Canada

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune disease treatment Stelara. With this approval, Celltrion announced on Wednesday that it can now sell Steqeyma in Canada for the treatment of plaque p

Celltrion’s new plant in Songdo poised for commercial production

Celltrion’s new plant in Songdo poised for commercial production

A bird's-eye view of Celltrion's Songdo campus in Incheon, South Korea South Korea’s largest biosimilar maker Celltrion Inc. said on Tuesday that its third plant in Sondgo, west of Seoul, is undergoing process valuation testing, or the final stage of inspection, before starting commercial

Celltrion's Remsima SC breaks 20% market share in Europe

Celltrion's Remsima SC breaks 20% market share in Europe

South Korea's biopharmaceutical company Celltrion Inc. said on Wednesday that its subcutaneous autoimmune disease treatment Remsima SC has surpassed a 20% market share in Europe during the first quarter of this year.Launched in 2020 as a subcutaneous formulation of its blockbuster drug Remsima
(* comment hide *}